Studying the effect of adding memantine to a long-acting stimulant on executive function deficits in adolescents with attention deficit hyperactivity disorder referred to a pediatric psychiatric clinic in 2015.

Investigating the effect of adding memantine to a long-acting stimulant on executive function deficits in adolescents with attention deficit hyperactivity disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250917067279N1

Enrollment

Registered

2026-01-20

Start date

2025-10-23

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit-hyperactivity disorder. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: First Intervention group: patients in this group are given memantine (Alzixa) orally, adding to long-acting stimulant, at a dose of 9 mg daily (divided in three doses daily). Intervent

Eligibility

Sex/Gender

All

Age

12 Years to 18 Years

Inclusion criteria

Inclusion criteria: Diagnosis of ADHD by a psychiatrist using a questionnaire Presence of functional deficits in the adolescent Age 12 to 18 years Normal intelligence quotient using an IQ test

Exclusion criteria

Exclusion criteria: Having any medical illness Using any medication except long-acting stimulant

Design outcomes

Primary

Measure	Time frame
Executive functioning score in the Brief questionnaire. Timepoint: Upon arrival and 30 days later. Method of measurement: BRIEF questionair.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Golmohammadi

Esfahan University of Medical Sciences

fgmohammadi@med.mui.ac.ir+98 31 3222 2127

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026